OverviewSuggest Edit

Abcam is a life sciences company that identifies and develops biological reagents and tools. The company provides antibodies, binders, and assays, including primary and secondary antibodies, ELISA and matched antibody pairs, knockout cell lines and lysates, multiplex assays, agonists, antagonists, activators, inhibitors, as well as proteins and peptides. Its products are applicable in research, drug discovery, and diagnostics.

TypePublic
Founded1998
HQCambridge, GB
Websiteabcam.com
Employee Ratings4.6

Latest Updates

Employees (est.) (Jun 2020)1,492(+30%)
Revenue (FY, 2020)£260 M
Share Price (Jan 2021)$23.5 (+2%)
Cybersecurity ratingBMore

Key People/Management at Abcam

Alan Hirzel

Alan Hirzel

Chief Executive Officer
Peter Allen

Peter Allen

Non-Executive Chairman
Jonathan Milner

Jonathan Milner

Deputy Chairman
Michael S Baldock

Michael S Baldock

Chief Financial Officer
Giles Kerr

Giles Kerr

Non-Executive Director
Show more

Abcam Office Locations

Abcam has offices in Cambridge, Branford, Burlingame, Eugene and in 4 other locations
Cambridge, GB (HQ)
Discovery Drive Cambridge Biomedical Campus, Trumpington
Hangzhou Shi, CN
1418-32 Moganshan Rd, Gongshu Qu
Shanghai, CN
Unit 5401, Bldg. 5, No. 338 Galileo Rd. Pudong
Hong Kong, HK
Lakeside 1, 8 Science and Technology Ave W, Science Park
Tokyo, JP
2-2-1 Nihonbashi Horidome-cho
Branford, CT, US
688 E Main St
Show all (9)

Abcam Financials and Metrics

Abcam Revenue

Embed Graph
View revenue for all periods
Abcam's revenue was reported to be £260 m in FY, 2020
GBP

Revenue (FY, 2020)

260.0m

Revenue growth (FY, 2019 - FY, 2020), %

0%

Gross profit (FY, 2020)

180.2m

Gross profit margin (FY, 2020), %

69.3%

Net income (FY, 2020)

12.5m

EBIT (FY, 2020)

10.5m

Market capitalization (20-Jan-2021)

5.3b

Closing stock price (20-Jan-2021)

23.5

Cash (30-Jun-2020)

187.3m

EV

5.4b
Abcam's current market capitalization is $5.3 b.
Annual
GBPFY, 2018FY, 2019FY, 2020

Revenue

233.2m259.9m260.0m

Revenue growth, %

11%0%

Cost of goods sold

70.2m76.7m79.8m

Gross profit

163.0m183.2m180.2m
Half Year
GBPH1, 2019H1, 2020

Revenue

124.7m138.2m

Cost of goods sold

37.1m41.9m

Gross profit

87.6m96.3m

Gross profit Margin, %

70%70%
Annual
GBPFY, 2018FY, 2019FY, 2020

Cash

90.2m87.1m187.3m

Accounts Receivable

24.9m29.3m31.4m

Inventories

29.6m36.0m40.7m

Current Assets

159.9m171.8m278.8m
Half Year
GBPH1, 2019H1, 2020

Cash

83.2m189.9m

Inventories

32.1m39.5m

Current Assets

146.1m277.4m

PP&E

32.7m41.0m
Annual
GBPFY, 2018FY, 2019FY, 2020

Net Income

62.2m45.0m12.5m

Depreciation and Amortization

12.9m15.4m29.9m

Inventories

(5.8m)(6.1m)(1.1m)

Accounts Payable

3.4m7.7m2.4m
Half Year
GBPH1, 2019H1, 2020

Net Income

27.7m26.1m

Depreciation and Amortization

6.9m6.4m

Inventories

(2.5m)(4.6m)

Accounts Payable

(1.3m)1.7m
GBPFY, 2018

Revenue/Employee

221.3k

Financial Leverage

1.2 x

P/E Ratio

32.5
Show all financial metrics

Abcam Operating Metrics

FY, 2018FY, 2019FY, 2020

Countries

140 140 130

Locations

11 11 15

Products

110 k122 k130 k
Show all operating metrics

Abcam Acquisitions / Subsidiaries

Company NameDateDeal Size
Abcam Trading (Shanghai) Co. Ltd.
Abcam US Group Holdings Inc.
Abcam (US) Ltd.
Epitomics Inc

Abcam Revenue Breakdown

Embed Graph

Abcam revenue breakdown by business segment: 93.5% from Catalogue and 6.5% from Custom Products and Licensing

Abcam revenue breakdown by geographic segment: 43.2% from The Americas, 26.7% from EMEA, 15.2% from China, 7.2% from Japan and 7.7% from Rest of Asia Pacific

Abcam Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Abcam Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Abcam Online and Social Media Presence

Embed Graph

Abcam News and Updates

Abcam plc Half Year Trading Update

Abcam returns to growth in first half with over 8% increase in constant currency revenue Abcam returns to growth in first half with over 8% increase in constant currency revenue

Abcam plc: Annual Report, Impact Report and Notice of AGM

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 September 2020 of its final results for the year ended 30 June 2020, the Abcam plc Annual Report a…

Abcam plc: Consultation on 2020 LTIP Awards

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consultation with shareholders on the Group’s overall LTIP structure and performance framework, including propos…

Insights on the Transfer Membrane Global Market to 2027 - Featuring Abcam, Advansta & ATTO Among Others

Dublin, Oct. 08, 2020 (GLOBE NEWSWIRE) -- The "Transfer Membrane - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. The publisher brings years of research experience to the 6th edition of this report. The 181-page report presents concise insight…

Cancer Research UK and Abcam Launch Custom Partnership to Accelerate Cancer Research

LONDON and CAMBRIDGE, England, July 7, 2020 /PRNewswire/ -- Today, Cancer Research UK, the world's largest independent funder of cancer research and Abcam plc, a global innovator in life science reagents and tools, are pleased to announce a new partnership for the development and...

Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell's Gene Editing Platform and Oncology Product Portfolio

CAMBRIDGE, England and MILPITAS, California, Jan. 30, 2020 /PRNewswire/ -- Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life...
Show more

Abcam Blogs

Lab new year resolutions

It’s that time of year again. Time to tell yourself you will do things. The things you keep meaning to do, but you don’t. January – the month of getting things in order. At least for a week or two. Then you go back to your old routine. Obviously, no one likes having to do […] The post Lab new year r…

Under the Microscope: PCR and COVID-19

What is PCR? Polymerase Chain Reactions (PCRs) are often used in research to amplify genetic material, and, as a scientist, you probably don’t give the process a second thought. However, the term PCR has now left the laboratory and worked its way into every household due to its use in the COVID-19 t…

Five things to be thankful for in your science-world

Many Americans think of Thanksgiving as the start of the holiday season and use it as a time to reflect on what they are thankful for in their lives. While Thanksgiving of 2020 will be different for many people due to COVID-19, perhaps this year, it is more important than ever to remember what we [……

How to benefit the most from virtual conferences or events?

In the previous article of this series, we discussed the benefits and limitations of virtual conferences. Despite limitations, virtual conferences still allow you to share your knowledge, get valuable feedback, and find opportunities for new collaborations. You shouldn’t miss the chance to catch up …

Virtual conferences: friend or foe?

Apart from the ‘aha’ moments, one of the biggest excitements in science is traveling to conferences and sharing your findings with other scientists. You get to present your research, gain valuable feedback, make useful connections, foster new collaborations, and just have a great time. However, sinc…

Twitter tips for Academics: how to tweet about your publication

In the previous article of this series, we discussed the benefits of tweeting your next publication and preprint, such as expanding your paper’s reach and boosting citations. Here we will share our top Twitter tips for academics on how exactly to compose a tweet about your new paper or preprint. Tel…
Show more

Abcam Frequently Asked Questions

  • When was Abcam founded?

    Abcam was founded in 1998.

  • Who are Abcam key executives?

    Abcam's key executives are Alan Hirzel, Peter Allen and Jonathan Milner.

  • How many employees does Abcam have?

    Abcam has 1,492 employees.

  • What is Abcam revenue?

    Latest Abcam annual revenue is £260 m.

  • What is Abcam revenue per employee?

    Latest Abcam revenue per employee is £174.3 k.

  • Who are Abcam competitors?

    Competitors of Abcam include BioLegend, Bio-Techne and Humanigen.

  • Where is Abcam headquarters?

    Abcam headquarters is located at Discovery Drive Cambridge Biomedical Campus, Trumpington, Cambridge.

  • Where are Abcam offices?

    Abcam has offices in Cambridge, Branford, Burlingame, Eugene and in 4 other locations.

  • How many offices does Abcam have?

    Abcam has 9 offices.